Trial Profile
A Phase II Evaluation of Abraxane in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 23 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2010 Results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).